If ESBL-producing organisms are suspected, which agents are preferred for empiric therapy?

• A. Carbapenems
• B. Third-generation cephalosporins
• C. Macrolides
• D. Fluoroquinolones

Answer: (A)

When an ESBL-producing organism is suspected, the goal is to use an antibiotic that ESBL enzymes cannot inactivate. ESBLs hydrolyze many beta-lactams, including penicillins and most third-generation cephalosporins, which makes those drugs unreliable for serious infections. Carbapenems, however, are stable to ESBLs and retain activity against ESBL-producing Enterobacterales, providing reliable empiric coverage while you obtain culture data. That’s why they are the preferred initial choice for empiric therapy in this scenario.

Be aware that not all carbapenems are identical in spectrum. Meropenem or imipenem/cilastatin are typically favored for broad coverage, including potential Pseudomonas, while ertapenem has limited activity against Pseudomonas and Acinetobacter and might be less suitable when those organisms are a concern. After susceptibilities return, you should narrow therapy or de-escalate as appropriate to avoid unnecessary broad-spectrum use.

Macrolides and fluoroquinolones are not reliable choices for empiric coverage of ESBL producers, and third-generation cephalosporins are likely ineffective due to ESBL hydrolysis.